Fig. 3From: Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trialA Proportion of patients achieving ACR response, B mean (± SE) change from study baseline in DAS28-4CRP, C proportion of patients achieving good EULAR response, and D proportion of patients achieving DAS-4CRP < 2.6 and ACR/EULAR remission (ITT population in TP3). ACR20/50/70, ACR criteria for ≥ 20%/50%/70% clinical improvement; DAS28-4CRP, Disease Activity Score in 28 joints: 4 components based on high-sensitivity C-reactive protein; ITT, intent-to-treat; SE, standard error; TP3, treatment period 3Back to article page